Understanding the IVDR Transition Timeline
The EU In Vitro Diagnostic Regulation (IVDR, Regulation 2017/746) introduced significant changes to the regulatory framework for in vitro diagnostic medical devices. While the regulation entered into application on 26 May 2022, the European Commission recognized the challenges faced by the industry and introduced extended transitional provisions.
Key Milestones
The transitional provisions, as amended by Regulation (EU) 2023/607, establish a staggered timeline based on device risk classification:
Class D devices — the highest risk category, including devices for detecting transmissible agents in blood and tissues — must comply with IVDR requirements by 26 May 2025. These devices require the most rigorous conformity assessment procedures, including involvement of EU Reference Laboratories.
Class C devices have a deadline of 26 May 2026. This category includes devices such as self-testing blood glucose monitors and companion diagnostics, which require Notified Body involvement under IVDR.
Class B and Class A sterile devices benefit from the longest transition, with a deadline of 26 May 2027. While these represent lower-risk categories, manufacturers must still ensure full IVDR compliance by this date.
Strategic Planning Recommendations
Manufacturers should begin their transition planning immediately, regardless of their device classification. Key strategic considerations include:
- Gap Analysis: Conduct a thorough gap analysis comparing your current IVDD documentation against IVDR requirements. Pay particular attention to performance evaluation requirements under Annex XIII.
- Notified Body Engagement: Engage with your chosen Notified Body early. The limited number of IVDR-designated Notified Bodies means capacity constraints are a real concern.
- Quality Management System Updates: Review and update your QMS to address new IVDR requirements, including enhanced post-market surveillance obligations and vigilance reporting.
- EUDAMED Preparation: Prepare for registration in the European Database on Medical Devices (EUDAMED), including UDI-DI assignment and device registration data.
Conclusion
The extended transitional provisions provide additional time, but manufacturers should not delay their compliance efforts. A structured, phased approach to IVDR transition will help ensure continuity of market access while meeting all regulatory requirements.